128 related articles for article (PubMed ID: 38620102)
1. Injectable Hydrogel Mucosal Vaccine Elicits Protective Immunity against Respiratory Viruses.
Fu W; Guo M; Zhou X; Wang Z; Sun J; An Y; Guan T; Hu M; Li J; Chen Z; Ye J; Gao X; Gao GF; Dai L; Wang Y; Chen C
ACS Nano; 2024 Apr; 18(17):11200-11216. PubMed ID: 38620102
[TBL] [Abstract][Full Text] [Related]
2. Oral Bacteria Combined with an Intranasal Vaccine Protect from Influenza A Virus and SARS-CoV-2 Infection.
Nagai M; Moriyama M; Ichinohe T
mBio; 2021 Aug; 12(4):e0159821. PubMed ID: 34399617
[TBL] [Abstract][Full Text] [Related]
3. Delivery of antigen to nasal-associated lymphoid tissue microfold cells through secretory IgA targeting local dendritic cells confers protective immunity.
Rochereau N; Pavot V; Verrier B; Jospin F; Ensinas A; Genin C; Corthésy B; Paul S
J Allergy Clin Immunol; 2016 Jan; 137(1):214-222.e2. PubMed ID: 26414879
[TBL] [Abstract][Full Text] [Related]
4. Thermal-sensitive hydrogel as adjuvant-free vaccine delivery system for H5N1 intranasal immunization.
Wu Y; Wei W; Zhou M; Wang Y; Wu J; Ma G; Su Z
Biomaterials; 2012 Mar; 33(7):2351-60. PubMed ID: 22192540
[TBL] [Abstract][Full Text] [Related]
5. Intranasal trans-sialidase-based vaccine against Trypanosoma cruzi triggers a mixed cytokine profile in the nasopharynx-associated lymphoid tissue and confers local and systemic immunogenicity.
Pacini MF; Balbi CB; Dinatale B; González FB; Prochetto E; De Hernández MA; Cribb P; Farré C; Espariz M; Blancato VS; Magni C; Marcipar I; Pérez AR
Acta Trop; 2023 May; 241():106889. PubMed ID: 36893830
[TBL] [Abstract][Full Text] [Related]
6. Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity.
Bento D; Staats HF; Gonçalves T; Borges O
Eur J Pharm Biopharm; 2015 Jun; 93():149-64. PubMed ID: 25818119
[TBL] [Abstract][Full Text] [Related]
7. A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.
Joseph A; Itskovitz-Cooper N; Samira S; Flasterstein O; Eliyahu H; Simberg D; Goldwaser I; Barenholz Y; Kedar E
Vaccine; 2006 May; 24(18):3990-4006. PubMed ID: 16516356
[TBL] [Abstract][Full Text] [Related]
8. Transmucosal Delivery of Nasal Nanovaccines Enhancing Mucosal and Systemic Immunity.
Xu Y; Yan X; Wei T; Chen M; Zhu J; Gao J; Liu B; Zhu W; Liu Z
Nano Lett; 2023 Nov; 23(22):10522-10531. PubMed ID: 37943583
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of Antigen Adjuvanted with AS04 and Its Deposition in the Upper Respiratory Tract after Intranasal Administration.
Xu H; Alzhrani RF; Warnken ZN; Thakkar SG; Zeng M; Smyth HDC; Williams RO; Cui Z
Mol Pharm; 2020 Sep; 17(9):3259-3269. PubMed ID: 32787271
[TBL] [Abstract][Full Text] [Related]
10. Intranasal vaccination with influenza HA/GO-PEI nanoparticles provides immune protection against homo- and heterologous strains.
Dong C; Wang Y; Gonzalez GX; Ma Y; Song Y; Wang S; Kang SM; Compans RW; Wang BZ
Proc Natl Acad Sci U S A; 2021 May; 118(19):. PubMed ID: 33941704
[TBL] [Abstract][Full Text] [Related]
11. Nasal aluminum (oxy)hydroxide enables adsorbed antigens to induce specific systemic and mucosal immune responses.
Xu H; Ruwona TB; Thakkar SG; Chen Y; Zeng M; Cui Z
Hum Vaccin Immunother; 2017 Nov; 13(11):2688-2694. PubMed ID: 28933668
[TBL] [Abstract][Full Text] [Related]
12. Modified pulmonary surfactant is a potent adjuvant that stimulates the mucosal IgA production in response to the influenza virus antigen.
Mizuno D; Ide-Kurihara M; Ichinomiya T; Kubo I; Kido H
J Immunol; 2006 Jan; 176(2):1122-30. PubMed ID: 16394001
[TBL] [Abstract][Full Text] [Related]
13. Immunoglobulin A (IgA) responses and IgE-associated inflammation along the respiratory tract after mucosal but not systemic immunization.
Hodge LM; Marinaro M; Jones HP; McGhee JR; Kiyono H; Simecka JW
Infect Immun; 2001 Apr; 69(4):2328-38. PubMed ID: 11254590
[TBL] [Abstract][Full Text] [Related]
14. Synthetic polyacrylate polymers as particulate intranasal vaccine delivery systems for the induction of mucosal immune response.
Zaman M; Simerska P; Toth I
Curr Drug Deliv; 2010 Apr; 7(2):118-24. PubMed ID: 20158484
[TBL] [Abstract][Full Text] [Related]
15. Solid-in-oil nanodispersions for intranasal vaccination: Enhancement of mucosal and systemic immune responses.
Kong Q; Kitaoka M; Tahara Y; Wakabayashi R; Kamiya N; Goto M
Int J Pharm; 2019 Dec; 572():118777. PubMed ID: 31678377
[TBL] [Abstract][Full Text] [Related]
16. Mucosal Immune Response in Nasal-Associated Lymphoid Tissue upon Intranasal Administration by Adjuvants.
Takaki H; Ichimiya S; Matsumoto M; Seya T
J Innate Immun; 2018; 10(5-6):515-521. PubMed ID: 29860261
[TBL] [Abstract][Full Text] [Related]
17. Nasal lymphoid tissue, intranasal immunization, and compartmentalization of the common mucosal immune system.
Wu HY; Russell MW
Immunol Res; 1997; 16(2):187-201. PubMed ID: 9212364
[TBL] [Abstract][Full Text] [Related]
18. Human immune responses elicited by an intranasal inactivated H5 influenza vaccine.
Ainai A; van Riet E; Ito R; Ikeda K; Senchi K; Suzuki T; Tamura SI; Asanuma H; Odagiri T; Tashiro M; Kurata T; Multihartina P; Setiawaty V; Pangesti KNA; Hasegawa H
Microbiol Immunol; 2020 Apr; 64(4):313-325. PubMed ID: 31957054
[TBL] [Abstract][Full Text] [Related]
19. Enhanced intranasal delivery of mRNA vaccine by overcoming the nasal epithelial barrier via intra- and paracellular pathways.
Li M; Zhao M; Fu Y; Li Y; Gong T; Zhang Z; Sun X
J Control Release; 2016 Apr; 228():9-19. PubMed ID: 26941035
[TBL] [Abstract][Full Text] [Related]
20. Intranasal Vaccination against HIV-1 with Adenoviral Vector-Based Nanocomplex Using Synthetic TLR-4 Agonist Peptide as Adjuvant.
Li M; Jiang Y; Gong T; Zhang Z; Sun X
Mol Pharm; 2016 Mar; 13(3):885-94. PubMed ID: 26824411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
